Parkinson's Disease Seven-Market Drug Forecast and Market Analysis

List of Tables

This report covers the 7 major markets and provides an Excel-based forecast model for the Parkinson's Disease market through 2033.

GlobalData estimated that the PD market was $3.4 billion across the 7MM in 2023. By the end of the forecast period in 2033, sales across these markets will reach $7.0 billion, increasing at a compound annual growth rate (CAGR) of 7.6%.

The major drivers of growth in the PD market will be the launch of several pipeline products including novel levodopa delivery systems, products targeting non-motor complications and the first ever drugs with disease modifying potential to enter and revolutionize the treatment landscape.

The patent expiry of leading drugs in the market will be the major barrier to market growth.

Scope

Overview of Parkinson's Disease, including epidemiology, symptoms, diagnosis, and disease management.
Annualized Parkinson's Disease therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the Parkinson's therapeutics market.
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Parkinson's treatment. The most promising candidates in late-stage development are profiled.
Analysis of the current and future market competition in the global Parkinson's Disease therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the 7MM Parkinson's Disease therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM Parkinson's Disease therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Product Code: GDHC324PIDR-7M

1 Parkinson's Disease: Executive Summary

1.1 Summary of Changes
1.2 The PD market will grow to $7.0 billion
1.3 Novel symptomatic treatments will continue to shape the PD market
1.4 Opportunities and challenges for disease-modifying therapies entering the PD market
1.5 What do physicians think?

2 Introduction

2.1 Catalyst
2.2 Related reports
2.3 Upcoming related reports

3 Disease Overview

3.1 Etiology and pathophysiology
- 3.1.1 Etiology
- 3.1.2 Pathophysiology
3.2 Classification or staging systems

4 Epidemiology

4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 Forecast methodology
- 4.4.1 Sources
- 4.4.2 Forecast assumptions and methods
- 4.4.3 Forecast assumptions and methods: diagnosed prevalent cases of PD
- 4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of PD by HY clinical staging
- 4.4.5 Forecast assumptions and methods: diagnosed prevalent cases of PD by inheritance type
- 4.4.6 Forecast assumptions and methods: diagnosed prevalent cases of PD by motor complications
- 4.4.7 Forecast assumptions and methods: diagnosed prevalent cases of PD by neuropsychiatric complications
4.5 Epidemiological forecast for PD (2023-33)
- 4.5.1 Diagnosed prevalent cases of PD
- 4.5.2 Age-specific diagnosed prevalent cases of PD
- 4.5.3 Sex-specific diagnosed prevalent cases of PD
- 4.5.4 Diagnosed prevalent cases of PD by HY clinical staging
- 4.5.5 Diagnosed prevalent cases of PD by type
- 4.5.6 Diagnosed prevalent cases of PD by inheritance type
- 4.5.7 Diagnosed prevalent cases of PD by motor complications
- 4.5.8 Diagnosed prevalent cases of PD by neuropsychiatric complications
4.6 Discussion
- 4.6.1 Epidemiological forecast insight
- 4.6.2 COVID-19 impact
- 4.6.3 Limitations of the analysis
- 4.6.4 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and treatment overview
5.2 KOL insights on disease management

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview
7.2 Effective treatment of motor complications - dyskinesia, off episodes, gait, and balance problems
7.3 New therapies for non-motor complications - psychosis and dementia
7.4 Neuroprotective or disease-modifying agents
7.5 Formulations that reduce pill burden

8 R&D Strategies

8.1 Overview
- 8.1.1 Development of novel targets - targeting cell and gene therapies and a-synuclein
- 8.1.2 Innovative drug delivery systems
- 8.1.3 Secondary indications, post marketing requirements, and drug repurposing
8.2 Clinical trials design
- 8.2.1 Reliable biomarkers of disease progression
- 8.2.2 Genetic studies required to learn about genetic subtypes of PD

9 Pipeline Assessment

9.1 Overview
9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview
10.2 Competitive assessment
- 10.2.1 Levodopa therapies
- 10.2.2 Dopamine agonists/combinations
- 10.2.3 Antiparkinsonian agents targeting motor complications
- 10.2.4 Assets targeting PD dementia
- 10.2.5 Neuroprotective and disease-modifying agents

11 Current and Future Players

11.1 Overview
11.2 Deal-making trends

12 Market Outlook

12.1 Global markets
- 12.1.1 Forecast
- 12.1.2 Drivers and barriers - global issues
12.2 US
- 12.2.1 Forecast
- 12.2.2 Key events
- 12.2.3 Drivers and barriers
12.3 5EU
- 12.3.1 Forecast
- 12.3.2 Key events
- 12.3.3 Drivers and barriers
12.4 Japan
- 12.4.1 Forecast
- 12.4.2 Key events
- 12.4.3 Drivers and barriers

13 Appendix

13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
- 13.3.1 Forecasting methodology
13.4 Primary research - KOLs interviewed for this report
13.5 Primary research - prescriber survey
13.6 About the Authors
- 13.6.1 Analyst
- 13.6.2 Therapy Area Director
- 13.6.3 Epidemiologist
- 13.6.4 Managing Epidemiologists
- 13.6.5 Vice President of Disease Intelligence and Epidemiology
- 13.6.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence
About GlobalData
Contact Us

Product Code: GDHC324PIDR-7M

List of Table

List of Tables

Table 1: Parkinson's disease: key metrics in the 7MM
Table 2: Summary of changes to Parkinson's Disease: Seven-Market Drug Forecast and Analysis report
Table 3: Modified HY scale of PD symptoms
Table 4: Movement Disorder Society-Sponsored Revision of the Unified PD Rating Scale (MDS-UPDRS), 2019
Table 5: Risk factors and comorbidities of PD
Table 6: Treatment guidelines for PD
Table 7: Top 10 deals by value, 2014-25
Table 8: PD market - global drivers and barriers, 2023-33
Table 9: Key events impacting sales for PD in the US, 2023-33
Table 10: PD market - drivers and barriers in the US, 2023-33
Table 11: Key events impacting sales for PD in the 5EU, 2023-33
Table 12: PD market - drivers and barriers in the US, 2023-33
Table 13: Key events impacting sales for PD in Japan, 2023 and 2033
Table 14: PD market - drivers and barriers in Japan, 2023-33
Table 15: High-prescribing physicians (non-KOLs) surveyed, by country

List of Figure

List of Figures

Figure 1: Global sales forecast by country for Parkinson's disease in 2023 and 2033
Figure 2: Analysis of the company portfolio gap in PD during the forecast period
Figure 3: Competitive assessment of the late-stage pipeline agents that are investigated for disease-modifying/neuroprotective properties that GlobalData expects to be licensed for the treatment of PD during the forecast period
Figure 4: 7MM, diagnosed prevalence of PD, both sexes, ages >=18 years, %, 2023
Figure 5: 7MM, sources used and not used to forecast the diagnosed prevalent cases of PD
Figure 6: 7MM, sources used to forecast the diagnosed prevalent cases of PD segmented by HY clinical staging
Figure 7: 7MM, sources used to forecast the diagnosed prevalent cases of PD segmented by inheritance type
Figure 8: 7MM, sources used to forecast the diagnosed prevalent cases of PD segmented by motor complications
Figure 9: 7MM, sources used to forecast the diagnosed prevalent cases of PD segmented by neuropsychiatric complications
Figure 10: 7MM, diagnosed prevalent cases of PD, N, both sexes, ages >=18 years, 2023
Figure 11: 7MM, age-specific diagnosed prevalent cases of PD, N, both sexes, 2023
Figure 12: 7MM, sex-specific diagnosed prevalent cases of PD, N, ages >=18 years, 2023
Figure 13: 7MM, diagnosed prevalent cases of PD by HY clinical staging, both sexes, ages >=18 years, N, 2023
Figure 14: 7MM, diagnosed prevalent cases of PD by type, both sexes, ages >=18 years, N, 2023
Figure 15: 7MM, diagnosed prevalent cases of PD by inheritance type, both sexes, ages >=18 years, N, 2023
Figure 16: 7MM, diagnosed prevalent cases of PD by motor complications, N, both sexes, ages >=18 years, 2023
Figure 17: 7MM, diagnosed prevalent cases of PD by neuropsychiatric complications, N, both sexes, 2023
Figure 18: Treatment algorithm for PD patients: Treatment of Motor Complications
Figure 19: Unmet needs and opportunities in PD
Figure 20: Overview of PD pipeline in the 7MM
Figure 21: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for PD in the 7MM during the forecast period
Figure 22: Competitive assessment of the pipeline levodopa therapies benchmarked against the SOC, Sinemet
Figure 23: Competitive assessment of the pipeline dopamine agonist drugs benchmarked against the SOC, Requip XL
Figure 24: Competitive assessment of the pipeline antiparkinsonian drugs benchmarked against the SOC, Gocovri
Figure 25: Competitive assessment of PD dementia agents benchmarked against the SOC, Exelon
Figure 26: Competitive assessment of the pipeline neuroprotective/DMT drugs benchmarked against the SOC, Azilect
Figure 27: Analysis of the company portfolio gap in PD during the forecast period
Figure 28: Global (7MM) sales forecast by country for PD in 2023 and 2033
Figure 29: Sales forecast by class for PD in the US in 2023 and 2033
Figure 30: Sales forecast by class for PD in the 5EU in 2023 and 2033
Figure 31: Sales forecast by class for PD in Japan in 2023 and 2033

Parkinson's Disease Seven-Market Drug Forecast and Market Analysis

Description

Table of Contents

List of Tables

Scope

Reasons to Buy

Table of Contents

Table of Contents

1 Parkinson's Disease: Executive Summary

2 Introduction

3 Disease Overview

4 Epidemiology

5 Disease Management

6 Current Treatment Options

7 Unmet Needs and Opportunity Assessment

8 R&D Strategies

9 Pipeline Assessment

10 Pipeline Valuation Analysis

11 Current and Future Players

12 Market Outlook

13 Appendix

List of Table

List of Tables

List of Figure

List of Figures